Committed to Helping You Get Your Genentech Medicine
Knowing what to expect can make all the difference. We can help you
through each step of getting your Genentech medicine.
Frequently Asked Questions
About Pulmozyme Access Solutions
What is Pulmozyme Access Solutions?
Pulmozyme Access Solutions is a resource for people who take a
Genentech medicine. We connect you to the medicine you need.
I Am Concerned About Paying for Pulmozyme
My co-pays for Pulmozyme are too high. How can you help me?
There may be options to help you get the Genentech medicine your doctor has prescribed. Pulmozyme Access Solutions can refer you to patient assistance options.
Getting My Medicine
Can I pick up my Genentech medicine from my local pharmacy?
You can’t get your Genentech medicine from your local pharmacy. Instead, it will come to you from a specialty pharmacy.
Your specialty pharmacy is different from your regular mail-order pharmacy. It handles drugs like Pulmozyme.
When we check your coverage, we also refer you to a specialty pharmacy your health insurance plan will cover.
How long will it take to get my medicine?
You might not be able to get your Genentech medicine right away. First, your doctor’s office or specialty pharmacy will have to check to make sure your health insurance plan covers your medicine. This is called a “benefits investigation.” They also might have to send some more information before your plan covers your medicine. This is called a “prior authorization.”
Enrolling in Pulmozyme Access Solutions
How do I enroll in Pulmozyme Access Solutions?
- You fill out a form called the PAN.
- Your doctor fills out a form called the SMN. You do not have to fill out anything on this form.
- Your doctor sends both of these forms to Pulmozyme Access Solutions.
There are 2 ways to fill out the PAN form:
- You can fill out the form online
- You can download and print it to fill out a paper copy
Why do I need to sign the PAN form?
The PAN form lets us discuss your health information with your doctor
and your health insurance plan. We can’t work with you without a
I submitted the PAN online or gave the signed PAN to my doctor. Is there anything else I need to do to enroll?
You do not need to do anything else, but your doctor does. He or she needs to submit a form called the SMN. The SMN tells us your doctor wants to treat you with Pulmozyme. Make sure your doctor has sent us the SMN so you get help from us.
You do not need to fill out anything on the SMN form.
My Health Plan Denied Coverage for Pulmozyme
My health insurance plan will not cover Pulmozyme. What do I do?
If your health insurance plan will not cover your Genentech medicine,
you and your doctor’s office can file an appeal. Contact your doctor
to ask if you should file an appeal.
We have resources to help you and your doctor file an appeal.
Does Pulmozyme Access Solutions send the appeal to my health insurance plan?
We have resources to help you and your doctor file an appeal. You or
your doctor’s office has to file the appeal directly with your health
How long does an appeal take?
This depends on your health insurance plan. You should ask your plan directly about its process. Sometimes the appeals process is quick. However, it can take several months if you have to appeal several times.
My Insurance Might Change
I am enrolled in Pulmozyme Access Solutions and my health insurance plan has changed. What do I do next?
If your insurance changes while you’re taking your Genentech
medicine, call us. We can help you understand your new coverage.
I no longer have a health insurance plan. What should I do?
GATCF helps people who don't have health insurance. It also helps
people who have health insurance but have trouble paying for their
Genentech medicine. If you qualify for GATCF, you could receive your
medicine for free.
It is your and your doctor's responsibility to complete and submit
all required paperwork to your health insurance plan. Genentech
cannot guarantee your plan will cover any treatments.
PAN=Patient Authorization and Notice of Request
for Transmission of Health Information to Genentech Access Solutions
and Genentech® Access to Care Foundation.
SMN=Statement of Medical Necessity.
Important Safety Information & Indication
What it Treats
Pulmozyme® (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.
In CF patients with an FVC ≥40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.
Important Safety Information
Pulmozyme should not be used in patients who are allergic to any of its ingredients.
Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
For further information, please see the Pulmozyme full Prescribing Information.
The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of PULMOZYME should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.
The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to ™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.